Recent Investment Analysts’ Ratings Changes for Thermo Fisher Scientific (TMO)

Several brokerages have updated their recommendations and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) in the last few weeks:

• 1/23/2026 – Thermo Fisher Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/10/2026 – Thermo Fisher Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 1/9/2026 – Thermo Fisher Scientific had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 1/9/2026 – Thermo Fisher Scientific had its price target raised by analysts at Stifel Nicolaus from $583.00 to $700.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/7/2026 – Thermo Fisher Scientific had its price target raised by analysts at TD Cowen from $654.00 to $696.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Thermo Fisher Scientific had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $650.00 price target on the stock.
• 12/15/2025 – Thermo Fisher Scientific had its price target raised by analysts at Wells Fargo & Company from $635.00 to $675.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Thermo Fisher Scientific was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $660.00 price target on the stock, up previously from $580.00.
• 12/9/2025 – Thermo Fisher Scientific is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $685.00 price target on the stock.
• 12/9/2025 – Thermo Fisher Scientific is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating and a $685.00 price target on the stock.
• 12/7/2025 – Thermo Fisher Scientific was upgraded by analysts at KeyCorp from a “sector weight” rating to an “overweight” rating. They now have a $750.00 price target on the stock.
• 12/2/2025 – Thermo Fisher Scientific had its price target raised by analysts at Morgan Stanley from $656.00 to $670.00. They now have an “overweight” rating on the stock.
• 12/1/2025 – Thermo Fisher Scientific was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were issued a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Frederick M. Lowery sold 6,912 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at $8,360,731.98. The trade was a 32.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 124,517 shares of company stock worth $72,363,568 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.